Drugs / bitopertin
bitopertin
also known as
RO4917838 · DISC-1459 · Bitopertina · Bitopertine · Paliflutine · R-1678 · RG1678 · RO-4917939
Small molecule targets SLC6A9 via inhibition
Trials 29 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07123363 | Jan 2026 → Dec 2035 | erythropoietic protoporphyria | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 1 | NCT02019290 | Feb → Mar 2014 | — | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT01665976 | Aug → Nov 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01543529 | Feb → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01438749 | Oct 2011 → May 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01510899 | Oct 2011 → Mar 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01495104 | Oct 2011 → Jan 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01433575 | Sep → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01356550 | Jun → Oct 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01365403 | Apr → Jul 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01116830 | Nov 2010 → Feb 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01183585 | Aug → Sep 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01613040 | Jan → Jul 2009 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01636492 | Nov 2005 → Aug 2006 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05828108 | Jul 2023 → Aug 2025 | Diamond-Blackfan anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05308472 | Oct 2022 → Feb 2024 | erythropoietic protoporphyria | Disc Medicine, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03271541 | Oct 2017 → Jun 2018 | beta thalassemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01674361 | Dec 2012 → Apr 2015 | obsessive-compulsive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01234779 | Feb 2011 → Sep 2012 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00616798 | Mar 2008 → Feb 2010 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05883748 | Aug 2023 → Jun 2028 expected | erythropoietic protoporphyria | Disc Medicine, Inc | Enrolling by invitation | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06910358 | Apr 2025 → Sep 2026 expected | X-linked erythropoietic protoporphyria | Disc Medicine, Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01235520 | Jan 2011 → Jul 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01192867 | Dec 2010 → May 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01192906 | Dec 2010 → Jul 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01235559 | Dec 2010 → Mar 2015 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01235585 | Dec 2010 → Sep 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01192880 | Nov 2010 → Jul 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07603401 | — | X-linked erythropoietic protoporphyria | Disc Medicine, Inc | Available | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bitopertin | “OBJECTIVE: To determine the efficacy and safety of bitopertin (RG1678), a glycine reuptake inhibitor, in patients with schizophrenia and predominant negative symptoms who were...” PMID 24696094 ↗ Jun 2014 |
| Known as | Bitopertina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1171829 ↗ |
| Known as | Bitopertine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1171829 ↗ |
| Known as | DISC-1459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05308472 ↗ |
| Known as | Paliflutine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1171829 ↗ |
| Known as | R-1678 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1171829 ↗ |
| Known as | RG1678 | “OBJECTIVE: To determine the efficacy and safety of bitopertin (RG1678), a glycine reuptake inhibitor, in patients with schizophrenia and predominant negative symptoms who were...” PMID 24696094 ↗ Jun 2014 |
| Known as | RO-4917939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1171829 ↗ |
| Known as | RO4917838 | “This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute...” NCT01234779 ↗17“A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)” NCT01235585 ↗ “A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia” NCT01192906 ↗ “bitopertin [RO4917838] level 1” NCT01235559 ↗ |
| Action | Inhibit | “Glycine transporter 1 inhibitor” CHEMBL1171829 ↗1“a glycine transport inhibitor” PMID 28318835 ↗ Mar 2017 |
| Modality | Small molecule | — CHEMBL1171829 ↗ |
| Route | Oral | “placebo 10mg, 30mg, or 60mg of RO4917838 once daily, p.o., as add-on therapy” NCT00616798 ↗ |
| Target | SLC6A9 | “Glycine transporter 1 inhibitor” CHEMBL1171829 ↗ |